Q2 EPS Estimate for Aprea Therapeutics Lifted by Analyst

Aprea Therapeutics, Inc. (NASDAQ:APRE) – HC Wainwright increased their Q2 2026 earnings per share estimates for shares of Aprea Therapeutics in a research report issued on Monday, August 10th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.22) for the quarter, up from their previous estimate of ($0.24). The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.22) EPS, FY2027 earnings at ($1.01) EPS and FY2028 earnings at ($1.05) EPS.

APRE has been the topic of several other reports. Oppenheimer began coverage on Aprea Therapeutics in a research note on Thursday, May 7th. They issued an “outperform” rating and a $5.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Finally, Wedbush dropped their target price on shares of Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Aprea Therapeutics has a consensus rating of “Hold” and an average target price of $4.07.

Aprea Therapeutics Price Performance

NASDAQ APRE opened at $0.66 on Wednesday. The business has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $0.77. Aprea Therapeutics has a one year low of $0.55 and a one year high of $1.79. The stock has a market capitalization of $8.17 million, a P/E ratio of -0.43 and a beta of 1.52.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%.

Institutional Trading of Aprea Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics in the fourth quarter valued at approximately $40,000. DRW Securities LLC purchased a new position in shares of Aprea Therapeutics during the fourth quarter valued at approximately $103,000. Finally, AIGH Capital Management LLC grew its holdings in Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after buying an additional 645,000 shares in the last quarter. 34.19% of the stock is owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.